ArticleIndian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India2025
Eyelash Rejuvenation Using Bimatoprost 0.03%: A Prospective Pilot Split-Face Study in Indian Population.
Article in Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ophthalmic bimatoprost has been used worldwide for treatment of glaucoma, and enhanced eyelash growth has been reported with such use. Dermal application of prevalent bimatoprost preparations for eyelash enhancement has been reported with adverse effects. Objective: This article assesses if revised formulation (Trulush) of bimatoprost 0.03% provides effective as well as safe eyelash enhancement in Indian population. Materials and Methods: Prospective split-face study was conducted for 12 weeks in willing subjects for their eyelash rejuvenation. Subjects completed the pre- and post-study questionnaires for subjective evaluation. Bimatoprost (Trulush) was applied on the upper eyelid margin once a day. Adverse events were also assessed. Objective evaluation was done using available digital scale and pre- and post-study photographs at 12 weeks. Results: All Subjects reported improvement in length, darkness, and density. Objective assessment corresponded with the subjective assessments. No significant adverse effects were reported by the subjects. Conclusion: Bimatoprost 0.03%, in the available formulation (Trulush), is found to be effective for topical application and eyelash rejuvenation by their increase in length, darkness, and density. There are no significant side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.